QSC RESEARCH GRADE
≥99% HPLC PurityMS ConfirmedJanoshik COAIn-House SPPS1-Region Domestic Shipping
What is Semaglutide?
Semaglutide 3mg provides a higher per-tablet oral dose of the long-acting GLP-1 receptor agonist for research protocols requiring greater receptor engagement. Six-fold the 500mcg formulation for dose-response characterisation, receptor saturation studies, and higher-concentration metabolic models. Research use only.
Research Applications
Dose-Response GLP-1R Studies
Receptor occupancy at 3mg vs 500mcg — EC50 placement, saturation kinetics
Stronger Appetite Suppression
Hypothalamic GLP-1R saturation, energy intake dose-dependency
Higher-Dose Metabolic Research
Greater insulin secretion, glucagon suppression, hepatic glucose output at 3mg
Oral Bioavailability Dose Scaling
SNAC absorption efficiency vs dose — linear vs non-linear oral uptake
Cardioprotective Mechanism
Higher-dose GLP-1R endothelial and cardiac signalling — plaque regression models
Quick Specs
| Form | Tablet — 3mg per tablet, 25-tablet bottle |
| CAS Number | 910463-68-2 |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | ~4113.6 Da |
| Compound Type | GLP-1 Receptor Agonist (Fatty Acid-Modified) |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house synthesis — Qingdao, China |
| Storage | Room temperature sealed | cool, dry storage | protect from moisture |
| Shelf Life | 24 months unopened |

